It's a phase II asset. I can accept 1b SOI with excellent data, novelty, and no competitors.
Yes, they are going to raise capital. The value of successfully controlling psilocin blood concentrations within the therapeutic window will substantially outweigh a cap raise in terms of value.
I've compared TYP to IHL in a previous post. They are quite different companies with very different opportunities.
It's a phase II asset. I can accept 1b SOI with excellent data,...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
